GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer

Xuemei Zhang¹
 Maosheng Huang²
 Xifeng Wu²
 Susan Kadlubar¹
 Jie Lin²
 Xinfeng Yu¹
 Chunyang Fan³
 Baitang Ning⁴
 Fred F Kadlubar^{1†}

¹University of Arkansas for Medical Sciences, Little Rock, Arkansas,

²The University of Texas MD Anderson Cancer Center, Houston, Texas, ³VA hospital, Little Rock, Arkansas, ⁴National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas, USA

[†]Fred F Kadlubar passed away on December 4, 2010.

Abstract: The objective of this study was to determine copy number variant (CNV) and promoter genetic variants in glutathione *S*-transferase Mu class 1 (*GSTM1*) and the risk of recurrence (REC)/second primary tumor (SPT) in patients with previously diagnosed early stage head and neck cancer. Among 441 subjects, 133 experienced REC and/or an SPT, while 308 had single primary disease. TaqMan real-time polymerase chain reaction was used to measure the exact copy number of *GSTM1* and direct sequencing was used to determine genetic variants in the *GSTM1* promoter region. Multivariate Cox regression analysis was performed to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) associated with copy number and genetic variants. REC/SPT-free survival times were compared by constructing Kaplan–Meier curves and differences between curves were tested by logrank test. Results showed a significantly decreased REC/SPT (HR = 0.57; 95% CI = 0.35–0.95) and longer REC/SPT-free survival in subjects with at least two copies of *GSTM1* compared with the *GSTM1* homozygous deletion, but not in those with one copy of *GSTM1*. The –498G, –426G, and –339T alleles were significantly associated with REC/SPT, with HRs of 0.11 (0.02–0.85), 0.28 (0.11–0.74) and 2.02 (1.07–3.82), respectively. Kaplan–Meier survival analysis showed that the –498G, –426G, and –339C alleles were also significantly associated with increased REC/SPT-free survival. Further haplotype analysis showed the haplotype P^{–498G–426G–339C} carriers had decreased REC/SPT with a HR of 0.09 (95% CI 0.01–0.71) and increased REC/SPT-free survival compared with those with haplotype P^{–498C–426A–339T}. The P^{–498C–426A–339T}-containing reporter construct had significantly increased luciferase expression. These results suggest that the *GSTM1* CNV and promoter haplotype are better predictors of REC/SPTs of head and neck cancer than just measuring the presence/absence of *GSTM1*.

Keywords: *GSTM1*, copy number variant, REC, SPT, single nucleotide polymorphism

Introduction

Head and neck cancer (HNC), which includes carcinomas of the oral cavity, pharynx, and larynx, is one of the most common human cancers worldwide. HNC accounts for 3%–5% of all cancers in the USA and it has been estimated that in 2012 more than 52,000 (40,250 oral and pharynx and 12,360 larynx) individuals will be diagnosed with HNC and 11,500 (7850 oral and pharynx and 3650 larynx) will die of the disease.¹ Treatment of HNC is limited in early stage disease to either radiotherapy or surgery.² However, post-stage treatment morbidity and mortality increases when patients experience recurrence of disease (REC) or develop a second primary tumor (SPT).³

Correspondence: Susan Kadlubar
 Division of Medical Genetics, University of Arkansas for Medical Sciences,
 4301 West Markham Street,
 #580, Little Rock, AR 72205, USA
 Tel +1 501 526 7957
 Fax +1 501 686 6639
 Email sakadlubar@uams.edu

SPTs and recurrences develop in up to 20% of patients within 5 years of curative treatment.⁴ Smoking and alcohol consumption are strongly associated with poor outcomes in HNC.^{5,6} In addition, inherited factors, including genetic variants at specific genes, have also been demonstrated to modify this risk.⁷

Glutathione *S*-transferase Mu (GSTM) class enzymes, members of the glutathione *S*-transferase (GST) superfamily of phase II drug-metabolizing enzymes, play an important role in protecting cells against xenobiotics by conjugating with glutathione to detoxify electrophilic compounds. The genes encoding the GSTM family are located on chromosome 1p13.3 in the order *GSTM4*, *GSTM2*, *GSTM1*, *GSTM5*, *GSTM3*.^{8,9} GSTM proteins have distinct tissue distribution: GSTM1 is a major Mu-class GST in the liver, the GSTM2 subunit is primarily associated with skeletal muscle, GSTM3 is enriched in testis, and GSTM5 is found in brain.¹⁰ It is well known that hepatic GSTM1 is highly polymorphic, and these genetic variations, which include copy number variants (CNVs) and common single nucleotide polymorphisms (SNPs), are likely to contribute to inter-individual differences in response to carcinogens and drugs. The homozygous deletion of the *GSTM1* gene, which results in the absence of the GSTM1 enzyme, is present in 48%–57% of Caucasians, 23%–41% of African Americans, 32%–53% of Asians, and 40%–53% of Hispanics.¹¹ Due to the important role of GSTM1 in the metabolism of carcinogens and drugs, this deletion variant in *GSTM1* has been demonstrated to contribute to cancer susceptibility as well as to the prognosis of certain cancers.^{12–17} Previous studies have assessed risk based on the presence or absence of the *GSTM1* gene, without determining the exact number of gene copies in individuals who possess GSTM1. Furthermore, potential functional promoter SNPs in the *GSTM1* gene could influence the protein expression level and thus change the response of cells to exogenous carcinogens and drugs. However, investigation into these promoter genetic variants is still limited.

In this study, we report the results of the association between exact CNVs and promoter SNPs in *GSTM1* with HNC REC/SPT. Our results indicate that this approach to assessing genetic variation within GSTM1 is a more superior prognostic biomarker than just determining the presence/absence of the gene and will aid in the identification of high-risk/poor-outcome individuals. Future replication studies in other independent cohorts are warranted to confirm these findings.

Methods

Human liver tissues and GST expression detection

A total of 111 human liver tissue samples were obtained from the US Cooperative Tissue Network (Birmingham, AL, USA) and liver cytosols were prepared by 100,000 *g* centrifugation of tissue homogenized in 20 mM Tris-hydrochloric acid (pH 7.8)-buffered 0.25 M sucrose containing 0.5 mM ethylenediaminetetraacetic acid, 20 μ M butylated hydroxytoluene, and 0.1 mM dithiothreitol, as previously described.¹⁸ GSTs were determined after glutathione-agarose affinity chromatography and wide-pore high-performance liquid chromatography, as described by Coles and Kadlubar.¹⁹

Study subjects

The study population has been described previously.^{4,20–23} Briefly, patients included in this study were stage I and II head and neck cases enrolled in the randomized Retinoid Head and Neck Second Primary Trial from 1991 to 1999 at MD Anderson Cancer Center, in which patients either received daily low dose (30 mg/day) of 13-*cis*-retinoic acid or placebo for 3 years. Patients must have remained cancer free for at least 16 weeks following surgery and/or radiation treatment to be enrolled in the trial. There were no recruitment restrictions on age, gender, or ethnicity. Before randomization, patients were given a structured questionnaire that elicited information on sociodemographic factors, tobacco-use history, alcohol consumption, and other exposures. Clinical data were obtained by medical chart review. The definitions of “second primary tumor” and “recurrence” following the Warren and Gates criteria were provided previously.⁴

This study included 441 head and neck patients. Among these cases, 133 experienced recurrence of disease and/or an SPT, while 308 had single primary disease. All patients signed written informed consent before participation in the study and the study was approved by the Institution Review Board of the University of Texas MD Anderson Cancer Center. “Never smokers” were individuals who had smoked less than 100 cigarettes during their lifetime. “Former smokers” were individuals who had stopped smoking for at least a year at the time of enrollment.

Determination of *GSTM1* copy number

The gene copy number of *GSTM1* within the genome was determined with a TaqMan copy number assay (Applied Biosystems, Foster City, CA, USA), which used genomic DNA as a template and ran as a triplex TaqMan real-time polymerase chain reaction (PCR) with *Rnase P* as the

reference gene, along with a well-characterized reference sample (Coriell Institute for Medical Research, Camden, NJ, USA) with two copies of *GSTM1* as a calibrator. Real-time PCR data were analyzed by the comparative Ct method to calculate relative changes in the copy number of *GSTM1*. All CNV genotypes were determined without knowledge of the REC/SPT status of the subjects.

Determination of genotypes in the promoter of *GSTM1*

GSTM1 promoter fragments from each individual were amplified using the forward primer (*GSTM1*-PF: 5'-CAG GTT GGA CAT TGT TCT CGT G-3') and reverse primer (*GSTM1*-PR: 5'-CAG CTG CTT CGC ACT TCC CT-3') to produce a 1924 bp fragment. Genetic variants were identified by direct sequencing of the PCR products with a GenomeLab DTCS Quick Start Kit in a Beckman GeXP Genome Analyzer (both from Beckman Coulter, Fullerton, CA, USA). The sequencing primers were *GSTM1*-seq1 (5'-GGA GTT TCT TCA GAC TCA CAA T-3'), *GSTM1*-seq2 (5'-CCT GGG CCT TAA AGC ATG AC-3'), and *GSTM1*-seq3 (5'-CACAGA CCA CAT TTC CTT TAC-3'). Genetic variants were identified using Codon-Code Aligner software (CodonCode, Dedham, MA, USA), a program for sequence assembly and mutation detection.

Construction of reporter plasmids

To verify whether identified SNPs influenced the transcriptional activity of *GSTM1*, we constructed eight reporter plasmids encompassing base pairs from -1687 to +87 of the human *GSTM1* gene promoter. The primers used to amplify the fragment were 5'-GAC TAC GCG TTA CTG AAG AAC ACA CAT GG-3' and 5'-GAA TAG ATC TGC GGA TGT CCC AGT ACC-3', which contain *Mlu I* and *Bgl II* restriction sites (the underlined sequences), respectively. After amplification using LA Taq polymerase (NEB, Ipswich, MA, USA), the PCR product with the *GSTM1* promoter was digested with *Mlu I* and *Bgl II* then inserted into a pGL3-basic vector (Promega, Madison, WI, USA) with the firefly luciferase gene as a reporter. The resulting construct was designated "pC-A-C" (with -498C, -426A, -339C) after sequence verification. This P^{-498C-426A-339C} construct was subsequently used as a template to generate seven other constructs containing all possible haplotypes (P^{-498C-426A-339T}, P^{-498C-426G-339C}, P^{-498C-426G-339T}, P^{-498G-426A-339C}, P^{-498G-426A-339T}, P^{-498G-426G-339C}, P^{-498G-426G-339T}) using the Quickchange Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA). All constructs were confirmed by direct sequencing using the Beckman GeXP Genome Analyzer.

Cell culture and luciferase assay

The squamous cell carcinoma oral cavity cell line T409 was cultured in Dulbecco's modified Eagle's medium/F12 medium supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 U/mL streptomycin (Invitrogen, Carlsbad, CA, USA) in a humidified, 5% CO₂ incubator at 37°C. For transient transfection, 10 × 10⁴ cells were plated in a 96-well plate and grown to 70%–80% confluence. LipofectamineTM 2000 (Invitrogen) was used to transfect *GSTM1*-pGL3 basic constructs and control plasmid pRL-SV40 into cells according to the manufacturer's protocol. Luciferase activity was measured using a TD20/20 luminometer (Turner Designs, Sunnyvale, CA, USA). The empty pGL3-basic vector was also transfected into cells as a control. Fold increase was calculated by defining the activity of empty pGL3 basic vector as 1. Differences were determined by *t*-test and a *P* value of <0.05 was considered significant.

Statistical methods

Multivariate Cox regression was used to estimate hazard ratios (HRs) associated with CNV, genotypes, or haplotypes along with 95% confidence intervals (CIs), while adjusting for confounding variables such as age, gender, smoking status, alcohol consumption, tumor site (larynx, oral cavity, and pharynx), stage (I or II), and randomization (13-cis-retinoic acid chemoprevention or placebo). Kaplan–Meier curves were constructed to compare event-free survival by CNV, genotypes, or haplotypes and logrank tests were performed to compare differences between survival curves. All analyses were performed using the Intercooled Stata statistical software package (v 10.0; Stata, College Station, TX, USA). All statistical tests were two sided and a *P* value of 0.05 was used as the criterion of statistical significance.

Results

GSTM1 protein expression

GSTM1 genetic variants

To verify the relationship between CNV and *GSTM1* expression, we tested 111 human liver samples. Of these, 50 (45.0%) subjects were without *GSTM1* expression and 61 subjects (55.0%) expressed *GSTM1* with about 145-fold *GSTM1* expression variation.

The results also showed that subjects with at least two copies have much higher *GSTM1* expression than those with only one copy number (0.339 vs 0.118, *P* < 0.001) (Figure 1). This could partially account for *GSTM1* expression variants among individuals, but among carriers with

Figure 1 Level of GSTM1 expression in human liver tissue. (A) Samples have been arranged in order of increasing expression. (B) levels of GSTM1 protein expression in liver tissue by GSTM1 copy number.

Note: *Expression level among two copies genotype was significantly higher than the one copy genotype ($P < 0.01$).

Abbreviations: CNV, copy number variant; GST, glutathione S-transferase; GSTM1, glutathione S-transferase Mu class I.

one copy of *GSTM1*, there was still an 80-fold variation in protein expression. Thus, we conducted resequencing of a 1924-bp section of the 5' promoter region and found multiple genetic variants (Table 1). However, due to the very small sample size, there was no significant correlation between the genetic variants and GSTM1 protein levels.

Genetic variation screening

Through TaqMan *GSTM1* CNV assay, we determined that 57% of the study subjects had the *GSTM1* homozygous deletion, 24% had one copy of *GSTM1*, and 19% had at least two copies of *GSTM1*. Of those with the *GSTM1* gene, we sequenced the full-length promoter region of *GSTM1* and identified one insert variant and 14 SNPs (Table 1). Among these, the $-888A>T$ and $-341C>T$ were novel

whereas the other SNPs had been previously deposited in the National Center for Biotechnology Information database (-1543 TTCT insertion [rs71794573], $-1529C>G$ [rs36210087], $-1490A>G$ [rs36209763], $-1143A>G$ [rs36209754], $-498G>C$ [rs412543], $-486C>G$ [rs3815029], $-471C>T$ [rs55791819], $-426G>A$ [rs412302], $-344C>T$ [rs4147561], $-343A>T$ [rs4147562], $-339C>T$ [rs4147563], $-304G>A$ [rs28549287], $-164 C>T$ [rs36208869]). The allele frequencies for these variants range from 0.07 to 0.47 (Table 1).

CNV of *GSTM1* and REC/SPT-free survival of HNC

Regression analysis revealed significantly decreased REC/SPT in subjects with at least two copies of *GSTM1* (odds ratio (OR) = 0.57; 95% CI = 0.35–0.95) but not in those with one copy of the gene (Table 2). Kaplan–Meier survival analysis revealed longer REC/SPT-free survival in patients with at least two copies of *GSTM1*. However, there was no significant difference between *GSTM1* null subjects and one-copy carriers (Figure 2). SNP analysis showed the G allele of $-498C>G$, the G allele of $-426A>G$, and the T allele of $-339C>T$ SNPs were

Table 1 List of genetic variants in the promoter of *GSTM1* identified in Caucasians

Genetic variants	Position*	rs number	MAF (%)
1. INS	–1542	NA	40.0
2. C/G	–1529	rs36210087	7.3
3. A/G	–1490	rs36209763	19.3
4. A/G	–1143	rs36209754	24.5
5. A/T	–888	NA	11.0
6. C/G	–498	rs412543	14.6
7. C/G	–486	rs3815029	9.9
8. C/T	–471	NA	12.8
9. A/G	–426	rs412302	26.7
10. C/T	–344	rs4147561	28.5
11. A/T	–343	rs4147562	25.8
12. C/T	–341	NA	15.9
13. C/T	–339	rs4147563	47.3
14. G/A	–304	rs28529287	18.5
15. T/C	–164	rs36208869	22.5

Note: *Upstream of the ATG start site of the *GSTM1* gene.

Abbreviations: GSTM1, glutathione S-transferase Mu class I; MAF, minor allele frequency; NA, not assigned; INS, insertion; CNV, copy number variant.

Table 2 Copy number frequencies of *GSTM1* and risk of SPT/REC in head and neck cancer

CNV	No SPT/REC, N (%)	SPT/REC, N (%)	HR (95% CI)*	P#	Logrank test [§]
0	167 (54.2)	85 (63.9)			0.07
1	76 (24.7)	29 (21.8)	0.73 (0.48–1.12)	0.15	
2+	65 (21.1)	19 (14.3)	0.57 (0.35–0.95)	0.03	

Notes: *Adjusted for age, sex, race, smoking status, alcohol consumption, tumor site, tumor stage, and randomization arm; #P values of multivariate Cox regression; §P values of logrank test.

Abbreviations: CI, confidence interval; GSTM1, glutathione S-transferase Mu class I; HR, hazard ratio; REC, recurrence; SPT, second primary tumor; CNV, copy number variant.

Figure 2 Kaplan-Meier plots of time (months) and REC/SPT-free survival in HNC patients according to *GSTM1* CNV.

Abbreviations: CNV, copy number variant; *GSTM1*, glutathione S-transferase Mu class I; HNC, head and neck cancer; REC, recurrence; SPT, second primary tumor.

significantly associated with REC/SPT in HNC patients with HR 0.11 (0.02–0.85), 0.28 (0.11–0.74), and 2.02 (1.07–3.82), respectively (Table 3). Kaplan-Meier survival analysis also demonstrated that the –498G, –426G, and –339C alleles were significantly associated with longer REC/SPT-free survival times in HNC subjects (Figure 3A–C).

Haplotypes of *GSTM1* promoter variants and REC/SPT-free survival of HNC

Three SNPs (–498C>G, –426A>G, and –339C>T) in the promoter of *GSTM1* were independently associated with REC/SPT in HNC patients and were used for the construction of haplotypes. We evaluated the influence of different haplotypes on REC/SPT in our study population. The data showed that the patients with haplotype P^{–498G–426G–339C} had decreased REC/SPT (HR = 0.09, 95% CI 0.01–0.71) compared with those with haplotype P^{–498C–426A–339T} (Table 4).

There was no significant difference between other haplotypes and haplotype P^{–498C–426A–339T} (Table 4). Kaplan-Meier survival estimates showed increased REC/SPT in haplotype P^{–498G–426G–339C} group when compared with haplotype P^{–498C–426A–339T} group (Figure 4).

Effect of *GSTM1* haplotypes on transcriptional activity

To evaluate the influence of *GSTM1* promoter SNPs on transcriptional activity, eight luciferase reporter constructs were generated. The sequences of these constructs encompassed the three SNPs (ie, –498G>C, –426G>A, and –339C>T) and were transiently transfected into T409 cells. As shown in Figure 5, reporter gene expression driven by haplotype P^{–498G–426G–339C} of *GSTM1* was 4.8-fold greater than with haplotype P^{–498C–426A–339T} ($P < 0.01$). There were also statistically significant differences between other haplotypes and haplotype P^{–498C–426A–339T} (Figure 5).

Discussion

This study explored the association between exact copy number of the *GSTM1* gene and REC/SPT of HNC in a cohort study and provided compelling evidence of an association between HNC outcome and *GSTM1* promoter SNPs/haplotype. One of the major findings is that the exact CNV can predict REC/SPT in a gene-dosage-dependent manner, with subjects having more than two copies of *GSTM1* exhibiting the lowest risk of REC/SPT and longest REC/SPT-free survival. Another key finding is that three promoter SNPs (–498C>G, –426A>G, and –339C>T) were significantly associated with REC/SPT in HNC and the haplotype P^{–498G–426G–339C} is associated with decreased risk of REC/SPT and improved REC/SPT-free survival. Moreover, it should be noted that all the significant associations remained significant after adjustment for cigarette

Table 3 Allele frequencies of *GSTM1* promoter SNPs and the risk of SPT/REC in head and neck cancer

SNPs	No SPT/REC, N (%)	SPT/REC, N (%)	HR (95% CI)*	P [#]	Logrank test [§]
–498 C>G					
Allele C	99 (69.72)	43 (30.28)	1.00 (Ref)		
Allele G	26 (96.30)	1 (3.70)	0.11 (0.02–0.85)	0.04	0.004
–426 A>G					
Allele A	79 (67.52)	38 (32.48)	1.00 (Ref)		
Allele G	46 (88.46)	6 (11.54)	0.28 (0.11–0.74)	0.01	0.002
–339 C>T					
Allele C	82 (80.39)	20 (19.61)	1.00 (Ref)		
Allele T	43 (64.18)	24 (35.82)	2.02 (1.07–3.82)	0.03	0.03

Notes: *Adjusted for age, sex, race, smoking status, alcohol consumption, tumor site, tumor stage, and randomization arm; [#]P values of multivariate Cox regression; [§]P values of logrank test.

Abbreviations: CI, confidence interval; *GSTM1*, glutathione S-transferase Mu class I; HR, hazard ratio; REC, recurrence; SNP, single nucleotide polymorphism; SPT, second primary tumor.

Figure 3 Kaplan-Meier estimates of time (months) and REC/SPT-free survival in HNC patients by *GSTM1* promoter SNPs. (A) *GSTM1*-498C>G SNP and REC/SPT-free survival. (B) *GSTM1*-426A>G SNP and REC/SPT-free survival. (C) *GSTM1*-339C>T SNP and REC/SPT-free survival.

Abbreviations: *GSTM1*, glutathione S-transferase Mu class I; HNC, head and neck cancer; REC, recurrence; SNP, single nucleotide polymorphism; SPT, second primary tumor.

smoking, alcohol consumption, tumor site, tumor stage, and demographic factors, supporting exact copy number of the *GSTM* and *GSTM1* promoter SNPs/haplotype as independent predictors of REC/SPT in HNC patients.

The incidence of HNC is increasing worldwide, and is associated with high mortality, especially in patients

Table 4 *GSTM1* haplotype frequencies and risk of SPT/REC in head and neck cancer

Haplotype	No SPT/REC, N (%)	SPT/REC, N (%)	HR* (95% CI)	P [#]
P-498C-426A-339T	39 (62.9)	23 (37.1)	1.00 (ref)	
P-498C-426A-339C	40 (72.7)	15 (27.3)	0.72 (0.37-1.42)	0.35
P-498C-426G-339T	4 (80.0)	1 (20.0)	0.50 (0.02-10.54)	0.66
P-498C-426G-339C	16 (80.0)	4 (20.0)	0.41 (0.14-1.47)	0.13
P-498G-426G-339C	26 (96.3)	1 (3.7)	0.09 (0.01-0.69)	0.02

Notes: *Adjusted for age, sex, race, smoking status, alcohol consumption, tumor site, tumor stage, and randomization arm; [#]P values of multivariate Cox regression.

Abbreviations: CI, confidence interval; *GSTM1*, glutathione S-transferase Mu class I; HR, hazard ratio; REC, recurrence; SPT, second primary tumor.

experiencing REC or a SPT.²⁴ Previous studies have suggested that continued smoking, alcohol drinking, and tumor prognostic factors appear to be associated with the likelihood of SPT development.^{4,25,26} Recently, genetic variants in multiple cellular pathways have been shown to be independent predictors of REC/SPT in HNC patients.²⁰⁻²³ Long-term exposure to certain carcinogens contributes to REC/SPT of HNC, which is an unquestionably smoking-related cancer²⁷⁻³⁰ and is tightly related to the metabolism of carcinogens. As one of the major hepatic drug-metabolizing enzymes, *GSTM1* plays an important role in the detoxification of carcinogens. At time of writing, at least 77 publications have reported on the association between the *GSTM1* deletion variant and head and neck squamous cell carcinomas (HNSCC)^{11,31} and seven publications have examined the association between the *GSTM1* deletion variant and outcomes of HNSCC.^{7,14,32,33} However, these studies have produced conflicting results concerning *GSTM1* absence and risk and outcomes of HNSCC.^{14,30,32,34,35} In our study, we used exact copy number

Figure 4 Kaplan-Meier estimates of time (months) and REC/SPT-free survival in HNC patients by in haplotype P-498G-426G-339C and P-498C-426A-339T.

Abbreviations: HNC, head and neck cancer; REC, recurrence; SPT, second primary tumor.

Figure 5 Transient reporter gene expression assays with constructs containing full-length *GSTM1* promoter. Luciferase expression of the eight constructs in T409 cells co-transfected with pRL-SV40 to standardize transfection efficiency.

Abbreviation: *GSTM1*, glutathione S-transferase Mu class I; RLU, relative luciferase units.

Note: *denotes significantly higher luciferase activity compared to other constructs.

of *GSTM1* instead of *GSTM1* presence/absence. We found that two or more copies of *GSTM1* conferred decreased risk of REC/SPT but one copy did not. In a prostate and bladder cancer study, researchers showed the exact copy number of *GSTM1* could predict the risk of bladder cancer, rather than just gene deletion.³⁶ Our finding is also consistent with another study that showed a gene-dosage effect between copy number of *GSTM1* and enzyme activity.³⁷

Besides copy number, functional promoter genetic variants could influence gene expression levels by altering the binding ability of transcriptional factors to the gene promoter. In silico prediction modeling indicated multiple putative binding sites of transcriptional factors, such as AP2, GATA1, PEA3, and RXR/RAR, in the promoter region of *GSTM1*. Moreover, increased active transcriptional activity in the region from -600 to +34 of *GSTM1* after response to the *Myb* gene has been reported.³⁸ In this study, we sequenced the promoter of *GSTM1* and found 14 genetic variants, including one insertion variant and 13 SNPs. Furthermore, we demonstrated that three SNPs (-498C>G, -426A>G, and -339C>T) are related to outcomes of HNC. To date, there is one other report related to SNPs in the promoter region of the *GSTM1* gene: in that study, Singh and colleagues selected three potentially functional SNPs and found -498C>G was associated with decreased risk of breast cancer.³¹ This is consistent with the present study in that -498G was related to reduced risk of REC and SPT and was also associated with increased REC/SPT-free survival in HNC. However, Yu et al reported that the -498G allele decreased gene transcription by 30%–40% by reducing the DNA-binding affinity of AP2

for the promoter region.³⁹ This finding is inconsistent with the results of their reported case-control study. Since there are 14 common genetic variants in the promoter region of *GSTM1*, it is possible that *GSTM1* transcription is regulated by multiple transcription factors and could be influenced by several genetic variants in the promoter of *GSTM1*. In our HNC cohort study, in addition to -498C>G SNP, we also demonstrated that -426A>G and -339T>C were significantly associated with decreased REC/SPT and increased REC/SPT-free survival. This implies the complexity of *GSTM1* regulation by different transcriptional factors.

Since three promoter SNPs were independently associated with HNC outcomes, we then constructed haplotypes to examine the concerted effects of these variants. We found significant decreased REC/SPT and increased REC/SPT-free survival in patients with haplotype P-498G-426G-339C. Furthermore, in vitro assays demonstrated that haplotype p-498G-426G-339C has more transcriptional activity than other haplotypes. These data also support haplotype analysis as a better way of predicting the outcomes of HNC than examining single genetic variants.

Our study has limitations due to its relatively small sample size, so we were not able to assess the combined effects of CNV and promoter haplotypes on HNC outcomes; as such, examination of a larger study population is needed to clarify this relationship. However, this study is ongoing and can therefore be re-examined as more patients are accrued. The findings presented here should also be validated in other populations.

Despite these limitations, our findings support the effect of promoter SNPs and CNV in *GSTM1* on the outcomes of HNC. Further study is needed on the regulation of *GSTM1* expression and the influence of genetic variants – including CNV, SNP, or insertion – on the expression of *GSTM1* in human populations.

Acknowledgments

This work was supported by the Arkansas Biosciences Institute, the University of Arkansas for Medical Sciences' Clinical Research Center, grant M01 RR14288. Fred Kadlubar passed away on December 4, 2010.

Disclosure

The authors declare no conflicts of interest in this work.

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin*. 2012;62(1):10–29.
2. Lefebvre JL. Current clinical outcomes demand new treatment options for SCCN. *Ann Oncol*. 2005;16 Suppl 6:vi7–vi12.

3. Argiris A, Brockstein BE, Haraf DJ, et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. *Clin Cancer Res*. 2004;10(6):1956–1962.
4. Khuri FR, Kim ES, Lee JJ, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. *Cancer Epidemiol Biomarkers Prev*. 2001;10(8):823–829.
5. Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MK, Kowalski LP. Factors that influence treatment decision in older patients with resectable head and neck cancer. *Laryngoscope*. 2007;117(5):835–840.
6. Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MK, Kowalski LP. Comorbidity is a prognostic factor in elderly patients with head and neck cancer. *Ann Surg Oncol*. 2007;14(4):1449–1457.
7. Hopkins J, Cescon DW, Tse D, et al. Genetic polymorphisms and head and neck cancer outcomes: a review. *Cancer Epidemiol Biomarkers Prev*. 2008;17(3):490–499.
8. Pearson WR, Vorachek WR, Xu SJ, et al. Identification of class-mu glutathione transferase genes GSTM1–GSTM5 on human chromosome 1p13. *Am J Hum Genet*. 1993;53(1):220–233.
9. Xu S, Wang Y, Roe B, Pearson WR. Characterization of the human class Mu glutathione S-transferase gene cluster and the GSTM1 deletion. *J Biol Chem*. 1998;273(6):3517–3527.
10. Rowe JD, Nieves E, Listowsky I. Subunit diversity and tissue distribution of human glutathione S-transferases: interpretations based on electrospray ionization-MS and peptide sequence-specific antisera. *Biochem J*. 1997;325(Pt 2):481–486.
11. Geisler SA, Olshan AF. GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGE review. *Am J Epidemiol*. 2001;154(2):95–105.
12. Song DK, Xing DL, Zhang LR, Li ZX, Liu J, Qiao BP. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. *Cancer Detect Prev*. 2009;32(5–6):416–423.
13. Golka K, Hermes M, Selinski S, et al. Susceptibility to urinary bladder cancer: relevance of rs9642880[T], GSTM1 0/0 and occupational exposure. *Pharmacogenet Genomics*. 2009;19(11):903–906.
14. Olivieri EH, da Silva SD, Mendonça FF, et al. CYP1A2*1C, CYP2E1*5B, and GSTM1 polymorphisms are predictors of risk and poor outcome in head and neck squamous cell carcinoma patients. *Oral Oncol*. 2009;45(9):e73–e79.
15. Syamala VS, Sreeja L, Syamala V, et al. Influence of germline polymorphisms of GSTT1, GSTM1, and GSTP1 in familial versus sporadic breast cancer susceptibility and survival. *Fam Cancer*. 2008;7(3):213–220.
16. Pandey SN, Jain M, Nigam P, Choudhuri G, Mittal B. Genetic polymorphisms in GSTM1, GSTT1, GSTP1, GSTM3 and the susceptibility to gallbladder cancer in North India. *Biomarkers*. 2006;11(3):250–261.
17. Sharma A, Mishra A, Das BC, Sardana S, Sharma JK. Genetic polymorphism at GSTM1 and GSTT1 gene loci and susceptibility to oral cancer. *Neoplasma*. 2006;53(4):309–315.
18. King RS, Teitel CH, Kadlubar FF. In vitro bioactivation of N-hydroxy-2-amino-alpha-carboline. *Carcinogenesis*. 2000;21(7):1347–1354.
19. Coles BF, Kadlubar FF. Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs? *Biofactors*. 2003;17(1–4):115–130.
20. Hildebrandt MA, Lippman SM, Etzel CJ, et al. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. *Clin Cancer Res*. 2012;18(13):3705–3713.
21. Wang J, Lippman SM, Lee JJ, et al. Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. *Carcinogenesis*. 2010;31(10):1755–1761.
22. Wu X, Spitz MR, Lee JJ, et al. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. *Cancer Prev Res (Phila)*. 2009;2(7):617–624.
23. Zhang X, Yang H, Lee JJ, et al. MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. *Carcinogenesis*. 2010;31(12):2118–2123.
24. Khuri FR, Lippman SM, Spitz MR, Lotan R, Hong WK. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. *J Natl Cancer Inst*. 1997;89(3):199–211.
25. Dikshit RP, Boffetta P, Bouchardy C, et al. Risk factors for the development of second primary tumors among men after laryngeal and hypopharyngeal carcinoma. *Cancer*. 2005;103(11):2326–2333.
26. Russo A, Crosignani P, Berrino F. Tobacco smoking, alcohol drinking and dietary factors as determinants of new primaries among male laryngeal cancer patients: a case-cohort study. *Tumori*. 1996;82(6):519–525.
27. Vineis P, Pirastu R. Aromatic amines and cancer. *Cancer Causes Control*. 1997;8(3):346–355.
28. Hashibe M, Brennan P, Strange RC, et al. Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. *Cancer Epidemiol Biomarkers Prev*. 2003;12(12):1509–1517.
29. Cheng L, Sturgis EM, Eicher SA, Char D, Spitz MR, Wei Q. Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. *Int J Cancer*. 1999;84(3):220–224.
30. Minard CG, Spitz MR, Wu X, Hong WK, Etzel CJ. Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. *Cancer*. 2006;106(12):2636–2644.
31. Singh M, Shah PP, Singh AP, et al. Association of genetic polymorphisms in glutathione S-transferases and susceptibility to head and neck cancer. *Mutat Res*. 2008;638(1–2):184–194.
32. Matthias C, Harréus U, Strange R. Influential factors on tumor recurrence in head and neck cancer patients. *Eur Arch Otorhinolaryngol*. 2006;263(1):37–42.
33. Zafereo ME, Sturgis EM, Aleem S, Chaung K, Wei Q, Li G. Glutathione S-transferase polymorphisms and risk of second primary malignancy after index squamous cell carcinoma of the head and neck. *Cancer Prev Res (Phila Pa)*. 2009;2(5):432–439.
34. Geisler SA, Olshan AF, Cai J, Weissler M, Smith J, Bell D. Glutathione S-transferase polymorphisms and survival from head and neck cancer. *Head Neck*. 2005;27(3):232–242.
35. Worrall SF, Corrigan M, High A, et al. Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. *Pharmacogenetics*. 1998;8(5):433–439.
36. Nørskov MS, Frikke-Schmidt R, Bojesen SE, Nordestgaard BG, Loft S, Tybjærg-Hansen A. Copy number variation in glutathione-S-transferase T1 and M1 predicts incidence and 5-year survival from prostate and bladder cancer, and incidence of corpus uteri cancer in the general population. *Pharmacogenomics J*. 2011;11(4):292–299.
37. McLellan RA, Oscarson M, Alexandrie AK, et al. Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. *Mol Pharmacol*. 1997;52(6):958–965.
38. Bartley PA, Keough RA, Lutwyche JK, Gonda TJ. Regulation of the gene encoding glutathione S-transferase M1 (GSTM1) by the Myb oncoprotein. *Oncogene*. 2003;22(48):7570–7575.
39. Yu KD, Di GH, Fan L, et al. A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer. *FASEB J*. 2009;23(7):2274–2287.

Pharmacogenomics and Personalized Medicine**Dovepress****Publish your work in this journal**

Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability. This journal is indexed on the American Chemical

Society's Chemical Abstracts Service (CAS). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journal>